Your browser doesn't support javascript.
loading
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis.
Zlotoff, Daniel A; Hassan, Malek Z O; Zafar, Amna; Alvi, Raza M; Awadalla, Magid; Mahmood, Syed S; Zhang, Lili; Chen, Carol L; Ederhy, Stephane; Barac, Ana; Banerji, Dahlia; Jones-O'Connor, Maeve; Murphy, Sean P; Armanious, Merna; Forrestal, Brian J; Kirchberger, Michael C; Coelho-Filho, Otavio R; Rizvi, Muhammad A; Sahni, Gagan; Mandawat, Anant; Tocchetti, Carlo G; Hartmann, Sarah; Gilman, Hannah K; Zatarain-Nicolás, Eduardo; Mahmoudi, Michael; Gupta, Dipti; Sullivan, Ryan; Ganatra, Sarju; Yang, Eric H; Heinzerling, Lucie M; Thuny, Franck; Zubiri, Leyre; Reynolds, Kerry L; Cohen, Justine V; Lyon, Alexander R; Groarke, John; Thavendiranathan, Paaladinesh; Nohria, Anju; Fradley, Michael G; Neilan, Tomas G.
Afiliação
  • Zlotoff DA; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Hassan MZO; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Zafar A; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Alvi RM; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Awadalla M; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mahmood SS; Cardio-Oncology Program, Cardiology Division, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA.
  • Zhang L; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Chen CL; Cardiology Division, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, New York, USA.
  • Ederhy S; Cardio-Oncology Program, Division of Cardiology, Hopitaux Universitaires Est Parisien, Paris, France.
  • Barac A; Cardio-Oncology Program, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA.
  • Banerji D; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Jones-O'Connor M; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Murphy SP; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Armanious M; Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center & Research Institute and University of South Florida, Tampa, Florida, USA.
  • Forrestal BJ; Cardio-Oncology Program, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA.
  • Kirchberger MC; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Coelho-Filho OR; Discipline of Cardiology, Department of Medicine, Faculty of Medical Science, State University of Campinas, Campinas, Brazil.
  • Rizvi MA; Division of Oncology and Hematology, Department of Medicine, Lehigh Valley Hospital, Allentown, Pennsylvania, USA.
  • Sahni G; Cardiology Division, Mount Sinai Medical Center, New York, New York, USA.
  • Mandawat A; Cardio-Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Tocchetti CG; Department of Translational Medical Sciences, Interdepartmental Center of Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Università degli Studi di Napoli Federico II, Naples, Italy.
  • Hartmann S; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Gilman HK; Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Zatarain-Nicolás E; Cardiology Department, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red CardioVascular (CIBER-CV), Madrid, Spain.
  • Mahmoudi M; Faculty of Medicine, University of Southampton, Southampton, UK.
  • Gupta D; Cardiology Division, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, New York, USA.
  • Sullivan R; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Ganatra S; Cardio-Oncology Program, Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
  • Yang EH; UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Heinzerling LM; Department of Dermatology and Allergy, LMU Klinikum, Munich, Germany.
  • Thuny F; Mediterranean University Center of Cardio-Oncology, Aix-Marseille University, North Hospital, Marseille, France.
  • Zubiri L; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Reynolds KL; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cohen JV; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lyon AR; Cardio-Oncology Service, Royal Brompton Hospital and Imperial College London, London, UK.
  • Groarke J; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Thavendiranathan P; Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Nohria A; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Fradley MG; Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center & Research Institute and University of South Florida, Tampa, Florida, USA.
  • Neilan TG; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA tneilan@mgh.harvard.edu.
J Immunother Cancer ; 9(3)2021 03.
Article em En | MEDLINE | ID: mdl-33653803
ABSTRACT

BACKGROUND:

Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis.

METHODS:

From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested.

RESULTS:

Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p<0.001 and p=0.009, respectively). In contrast, the QTc interval at the time of myocarditis (435±39 ms) was not increased compared with pre-myocarditis baseline (422±27 ms, p=0.42). A prolonged QRS duration conferred an increased risk of subsequent MACE (HR 3.28, 95% CI 1.98 to 5.62, p<0.001). After adjustment, each 10 ms increase in the QRS duration conferred a 1.3-fold increase in the odds of MACE (95% CI 1.07 to 1.61, p=0.011). Conversely, there was no association between the QTc interval and MACE among men (HR 1.33, 95% CI 0.70 to 2.53, p=0.38) or women (HR 1.48, 95% CI 0.61 to 3.58, p=0.39).

CONCLUSIONS:

The QRS duration is increased in ICI myocarditis and is associated with increased MACE risk. Use of this widely available ECG parameter may aid in ICI myocarditis diagnosis and risk-stratification.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Potenciais de Ação / Eletrocardiografia / Inibidores de Checkpoint Imunológico / Sistema de Condução Cardíaco / Frequência Cardíaca / Miocardite Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Potenciais de Ação / Eletrocardiografia / Inibidores de Checkpoint Imunológico / Sistema de Condução Cardíaco / Frequência Cardíaca / Miocardite Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos